ERBB2 and breast carcinoma: HR‐positive, HER2‐positive breast cancer (triple‐positive breast cancer [TPBC]) tends to respond clinically to neoadjuvant targeted therapy more often than HR‐negative, HER2‐positive breast cancer due to crosstalk between HER2 and hormone receptor (HR) signaling pathways.